velusetrag | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Summary of Clinical Trials for Chronic Constipation | Download Table
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study - Kuo - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Frontiers | Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders | Pharmacology
Velusetrag - Wikipedia
VELUSETRAG
Tryptophan Metabolism as a Pharmacological Target: Trends in Pharmacological Sciences
Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis - The Lancet Gastroenterology & Hepatology
Velusetrag (TD-5108) | 5-HT4R Agonist | MedChemExpress
Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis | Gut
UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K THERAVANCE BIOPHARMA, INC.
Diabetic gastroparesis: current challenges and future prospects | CEG
PDF) Velusetrag for the treatment of chronic constipation
Velusetrag - an overview | ScienceDirect Topics
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Is Alfasigma late reporting EU clinical trials?
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
Percent change in gastric emptying half‐time from baseline after... | Download Scientific Diagram
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Receptor binding profile of 5-HT 4 agonists for GI disorders, at... | Download Table
Buy Velusetrag (bt-285965)| THE BioTek
Theravance Biopharma :: SEC Filing
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
